Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 25 studies | 31% ± 15% | |
astrocyte | 17 studies | 39% ± 18% | |
oligodendrocyte | 14 studies | 40% ± 15% | |
macrophage | 12 studies | 33% ± 16% | |
microglial cell | 12 studies | 37% ± 12% | |
oligodendrocyte precursor cell | 12 studies | 41% ± 17% | |
fibroblast | 12 studies | 30% ± 13% | |
glutamatergic neuron | 11 studies | 44% ± 24% | |
GABAergic neuron | 10 studies | 46% ± 23% | |
epithelial cell | 9 studies | 37% ± 19% | |
adipocyte | 9 studies | 34% ± 10% | |
pericyte | 8 studies | 34% ± 15% | |
smooth muscle cell | 8 studies | 25% ± 8% | |
interneuron | 7 studies | 51% ± 23% | |
myeloid cell | 7 studies | 27% ± 6% | |
basal cell | 7 studies | 30% ± 19% | |
neuron | 6 studies | 45% ± 22% | |
retinal cone cell | 6 studies | 22% ± 8% | |
dendritic cell | 6 studies | 25% ± 5% | |
ciliated cell | 6 studies | 28% ± 9% | |
endothelial cell of lymphatic vessel | 6 studies | 34% ± 14% | |
type I pneumocyte | 6 studies | 28% ± 10% | |
type II pneumocyte | 6 studies | 31% ± 10% | |
retinal ganglion cell | 5 studies | 31% ± 15% | |
amacrine cell | 5 studies | 27% ± 8% | |
retina horizontal cell | 5 studies | 30% ± 11% | |
cardiac muscle cell | 5 studies | 29% ± 6% | |
mast cell | 5 studies | 24% ± 7% | |
Mueller cell | 5 studies | 32% ± 13% | |
respiratory goblet cell | 5 studies | 33% ± 14% | |
monocyte | 5 studies | 28% ± 7% | |
club cell | 5 studies | 32% ± 9% | |
granule cell | 4 studies | 34% ± 5% | |
B cell | 4 studies | 23% ± 6% | |
plasma cell | 4 studies | 41% ± 8% | |
retinal bipolar neuron | 4 studies | 25% ± 6% | |
mesothelial cell | 4 studies | 29% ± 9% | |
lymphocyte | 4 studies | 32% ± 11% | |
retinal rod cell | 4 studies | 30% ± 6% | |
T cell | 4 studies | 23% ± 5% | |
natural killer cell | 4 studies | 22% ± 4% | |
goblet cell | 4 studies | 35% ± 25% | |
classical monocyte | 3 studies | 20% ± 3% | |
hematopoietic precursor cell | 3 studies | 22% ± 5% | |
GABAergic interneuron | 3 studies | 40% ± 4% | |
glial cell | 3 studies | 25% ± 7% | |
CD4-positive, alpha-beta T cell | 3 studies | 19% ± 1% | |
mononuclear phagocyte | 3 studies | 22% ± 6% | |
vein endothelial cell | 3 studies | 36% ± 22% | |
GABAergic amacrine cell | 3 studies | 31% ± 10% | |
glycinergic amacrine cell | 3 studies | 30% ± 6% | |
rod bipolar cell | 3 studies | 28% ± 11% | |
hepatocyte | 3 studies | 61% ± 21% | |
retinal pigment epithelial cell | 3 studies | 43% ± 27% | |
abnormal cell | 3 studies | 33% ± 22% | |
neural progenitor cell | 3 studies | 35% ± 4% | |
ependymal cell | 3 studies | 44% ± 15% | |
leukocyte | 3 studies | 26% ± 8% | |
alveolar macrophage | 3 studies | 35% ± 11% | |
capillary endothelial cell | 3 studies | 20% ± 4% | |
transit amplifying cell | 3 studies | 40% ± 32% | |
mural cell | 3 studies | 33% ± 11% | |
mucus secreting cell | 3 studies | 35% ± 9% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 17 studies | 40% ± 21% | |
eye | 7 studies | 32% ± 18% | |
lung | 6 studies | 25% ± 9% | |
heart | 4 studies | 25% ± 5% | |
liver | 4 studies | 35% ± 18% | |
peripheral blood | 3 studies | 18% ± 2% | |
intestine | 3 studies | 19% ± 2% | |
adipose | 3 studies | 33% ± 5% | |
kidney | 3 studies | 26% ± 7% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
breast | 100% | 4886.66 | 459 / 459 | 100% | 21.82 | 1118 / 1118 |
esophagus | 100% | 4026.27 | 1445 / 1445 | 100% | 17.72 | 183 / 183 |
prostate | 100% | 4012.44 | 245 / 245 | 100% | 20.68 | 502 / 502 |
lung | 100% | 4076.57 | 578 / 578 | 100% | 14.69 | 1154 / 1155 |
intestine | 100% | 4244.83 | 966 / 966 | 100% | 14.63 | 526 / 527 |
ovary | 100% | 4894.23 | 180 / 180 | 100% | 12.86 | 429 / 430 |
thymus | 100% | 4379.00 | 653 / 653 | 100% | 17.44 | 603 / 605 |
stomach | 100% | 3470.06 | 359 / 359 | 100% | 15.32 | 285 / 286 |
brain | 100% | 3068.66 | 2636 / 2642 | 100% | 18.46 | 703 / 705 |
pancreas | 100% | 3292.75 | 328 / 328 | 99% | 13.45 | 177 / 178 |
kidney | 100% | 3254.43 | 89 / 89 | 99% | 16.33 | 894 / 901 |
bladder | 100% | 4109.86 | 21 / 21 | 99% | 11.04 | 499 / 504 |
skin | 100% | 5982.75 | 1809 / 1809 | 99% | 19.35 | 466 / 472 |
uterus | 100% | 4945.69 | 170 / 170 | 98% | 11.63 | 450 / 459 |
adrenal gland | 100% | 4830.71 | 258 / 258 | 95% | 11.65 | 219 / 230 |
liver | 100% | 1885.50 | 226 / 226 | 86% | 6.70 | 350 / 406 |
adipose | 100% | 4347.48 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 4398.95 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 11.98 | 29 / 29 |
muscle | 100% | 5383.57 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 4267.12 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 13.62 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 4.87 | 1 / 1 |
eye | 0% | 0 | 0 / 0 | 98% | 15.02 | 78 / 80 |
heart | 97% | 2992.53 | 836 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 91% | 2610.89 | 843 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0009791 | Biological process | post-embryonic development |
GO_0048009 | Biological process | insulin-like growth factor receptor signaling pathway |
GO_0007631 | Biological process | feeding behavior |
GO_0008344 | Biological process | adult locomotory behavior |
GO_0050885 | Biological process | neuromuscular process controlling balance |
GO_0035264 | Biological process | multicellular organism growth |
GO_0016441 | Biological process | post-transcriptional gene silencing |
GO_0061157 | Biological process | mRNA destabilization |
GO_0072344 | Biological process | rescue of stalled ribosome |
GO_0048873 | Biological process | homeostasis of number of cells within a tissue |
GO_0045947 | Biological process | negative regulation of translational initiation |
GO_0060339 | Biological process | negative regulation of type I interferon-mediated signaling pathway |
GO_0031571 | Biological process | mitotic G1 DNA damage checkpoint signaling |
GO_0050881 | Biological process | musculoskeletal movement |
GO_0021522 | Biological process | spinal cord motor neuron differentiation |
GO_0017148 | Biological process | negative regulation of translation |
GO_0016020 | Cellular component | membrane |
GO_0043204 | Cellular component | perikaryon |
GO_0032991 | Cellular component | protein-containing complex |
GO_0005794 | Cellular component | Golgi apparatus |
GO_1990635 | Cellular component | proximal dendrite |
GO_0005783 | Cellular component | endoplasmic reticulum |
GO_0005829 | Cellular component | cytosol |
GO_0005768 | Cellular component | endosome |
GO_0031982 | Cellular component | vesicle |
GO_0010494 | Cellular component | cytoplasmic stress granule |
GO_0060090 | Molecular function | molecular adaptor activity |
GO_0070064 | Molecular function | proline-rich region binding |
GO_0045296 | Molecular function | cadherin binding |
GO_0003723 | Molecular function | RNA binding |
GO_0005515 | Molecular function | protein binding |
Gene name | GIGYF2 |
Protein name | GRB10-interacting GYF protein 2 (PERQ amino acid-rich with GYF domain-containing protein 2) (Trinucleotide repeat-containing gene 15 protein) GRB10 interacting GYF protein 2 |
Synonyms | PERQ2 KIAA0642 TNRC15 |
Description | FUNCTION: Key component of the 4EHP-GYF2 complex, a multiprotein complex that acts as a repressor of translation initiation . In the 4EHP-GYF2 complex, acts as a factor that bridges EIF4E2 to ZFP36/TTP, linking translation repression with mRNA decay . Also recruits and bridges the association of the 4EHP complex with the decapping effector protein DDX6, which is required for the ZFP36/TTP-mediated down-regulation of AU-rich mRNA . May act cooperatively with GRB10 to regulate tyrosine kinase receptor signaling, including IGF1 and insulin receptors . In association with EIF4E2, assists ribosome-associated quality control (RQC) by sequestering the mRNA cap, blocking ribosome initiation and decreasing the translational load on problematic messages. Part of a pathway that works in parallel to RQC-mediated degradation of the stalled nascent polypeptide . GIGYF2 and EIF4E2 work downstream and independently of ZNF598, which seems to work as a scaffold that can recruit them to faulty mRNA even if alternative recruitment mechanisms may exist . .; FUNCTION: (Microbial infection) Upon SARS coronavirus-2/SARS-CoV-2 infection, the interaction with non-structural protein 2 (nsp2) enhances GIGYF2 binding to EIF4E2 and increases repression of translation initiation of genes involved in antiviral innate immune response such as IFNB1. . |
Accessions | ENST00000677450.1 C9JXQ0 C9JPV7 C9JHW1 I1E4Y6 ENST00000488734.5 ENST00000490612.5 C9JHT0 ENST00000424038.2 C9JW88 A0A7I2V3X3 ENST00000629305.2 ENST00000678230.1 A0A7I2V3H0 ENST00000475359.6 ENST00000421433.5 ENST00000425040.5 ENST00000490229.5 A0A7I2V516 ENST00000409547.5 [Q6Y7W6-1] ENST00000464805.5 ENST00000456491.5 ENST00000489328.1 ENST00000464402.5 ENST00000373563.9 [Q6Y7W6-1] A0A7I2V3H7 F8WBF1 ENST00000483164.5 C9JC65 Q6Y7W6 ENST00000476995.5 C9JRZ2 ENST00000492910.5 ENST00000678339.1 ENST00000676848.1 ENST00000409451.7 [Q6Y7W6-3] ENST00000678466.1 E7ESB6 ENST00000458528.1 ENST00000409480.5 ENST00000429187.5 ENST00000440945.5 A0A7I2V361 ENST00000678885.1 ENST00000423659.5 A0A7I2YQP8 ENST00000430720.5 ENST00000409196.7 [Q6Y7W6-5] F8WCD5 ENST00000677591.1 ENST00000428883.5 ENST00000427233.5 ENST00000482666.5 C9J0V6 |